GlaxoSmithKline and Sanofi Announce Positive Test Results for Covid-19 Booster Vaccine

Strategic Insights -

GlaxoSmithKline and Sanofi have announced positive results for their Covid-19 booster vaccine candidate, with consistently strong immune responses shown in a booster jab. The trial, the most comprehensive booster trial to date, explored boosting across different vaccine technologies used for primary vaccination. The companies plan to file the booster data with regulators following full phase III results, and the booster vaccine could potentially be available to help protect people over time.

Key Takeaways:

  • The booster jab delivered consistently strong immune responses, with neutralising antibodies increasing in the 9- to 43-fold range.
  • The booster was well tolerated, with a safety profile similar to currently approved Covid-19 vaccines.
  • The trial explored boosting across different vaccine technologies used for primary vaccination, including AstraZeneca, Johnson & Johnson, Moderna, and Pfizer vaccines.
  • The companies plan to file the booster data with regulators following full phase III results.
  • The initial booster data are promising, and the companies await the Phase 3 results to determine the next steps on making protein-based adjuvanted Covid-19 vaccines available.
  • The companies are pursuing a phase III trial to support submissions of their booster vaccine as quickly as possible.
  • The pandemic threat continues with the current dominant Delta variant and Omicron rapidly gaining ground, making booster vaccines essential to help protect people over time.

Statistics:

  • 9- to 43-fold increase in neutralising antibodies after the booster jab.
  • The safety profile of the booster vaccine was similar to that of currently approved Covid-19 vaccines.
  • The trial explored boosting across different vaccine technologies used for primary vaccination, including AstraZeneca, Johnson & Johnson, Moderna, and Pfizer vaccines.
  • The companies plan to file the booster data with regulators following full phase III results.

Sources:

  • Commerce News
  • AstraZeneca PLC
  • Johnson & Johnson
  • Moderna Inc
  • Pfizer Inc
  • Greg Roxburgh, Alliance News
  • (Copyright 2021 Alliance News Limited. All Rights Reserved.)